Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 50016221
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166561(Naphthalene-1-sulfonic acid {4-[(4-amino-quinazoli...)
Affinity DataIC50: 1.30nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166554(N-{4-[(4-Amino-quinazolin-2-ylamino)-methyl]-cyclo...)
Affinity DataIC50: 1.60nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166552(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 2.5nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166555(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 2.70nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166559(Butane-1-sulfonic acid {4-[(4-dimethylamino-quinaz...)
Affinity DataIC50: 4.90nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166551(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 5.60nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166555(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 7.70nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166552(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 21nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166563(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 31nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166564(N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methy...)
Affinity DataIC50: 41nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166563(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 47nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166565(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexyl]-2-...)
Affinity DataIC50: 57nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166559(Butane-1-sulfonic acid {4-[(4-dimethylamino-quinaz...)
Affinity DataIC50: 58nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166562(4-Bromo-N-[4-(quinazolin-2-ylaminomethyl)-cyclohex...)
Affinity DataIC50: 78nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166565(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexyl]-2-...)
Affinity DataIC50: 83nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166564(N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methy...)
Affinity DataIC50: 86nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166561(Naphthalene-1-sulfonic acid {4-[(4-amino-quinazoli...)
Affinity DataIC50: 97nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166554(N-{4-[(4-Amino-quinazolin-2-ylamino)-methyl]-cyclo...)
Affinity DataIC50: 100nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166560(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 110nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166557(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexylmeth...)
Affinity DataIC50: 120nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166557(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexylmeth...)
Affinity DataIC50: 130nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166557(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexylmeth...)
Affinity DataIC50: 140nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166562(4-Bromo-N-[4-(quinazolin-2-ylaminomethyl)-cyclohex...)
Affinity DataIC50: 140nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166555(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 140nMAssay Description:Inhibitory activity against human wild type Melanin concentrating hormone receptor 1 induced calcium flux stably expressed in HEK293 cells (n=6)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166560(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 150nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166555(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 160nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetAlpha-2A adrenergic receptor(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166556(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 170nMAssay Description:Inhibitory activity against constitutively activated human Alpha-2A adrenergic receptor transiently expressed in COS-1 cells using [3H]MK-912More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166555(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 200nMAssay Description:Inhibitory activity against human wild type Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 cells using [125I](Phe13,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166556(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 250nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166552(4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamin...)
Affinity DataIC50: 810nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166565(4-Bromo-N-[4-(quinazolin-2-ylamino)-cyclohexyl]-2-...)
Affinity DataIC50: 880nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166560(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166554(N-{4-[(4-Amino-quinazolin-2-ylamino)-methyl]-cyclo...)
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166563(4-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino...)
Affinity DataIC50: 2.20E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166558(4-Bromo-N-[4-(quinazolin-2-ylaminomethyl)-cyclohex...)
Affinity DataIC50: 2.70E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166559(Butane-1-sulfonic acid {4-[(4-dimethylamino-quinaz...)
Affinity DataIC50: 2.90E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166562(4-Bromo-N-[4-(quinazolin-2-ylaminomethyl)-cyclohex...)
Affinity DataIC50: 2.90E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166551(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 3.00E+3nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166561(Naphthalene-1-sulfonic acid {4-[(4-amino-quinazoli...)
Affinity DataIC50: 3.50E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166551(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 6.00E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166550(Octane-1-sulfonic acid {4-[(4-dimethylamino-quinaz...)
Affinity DataIC50: 6.70E+3nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeuropeptide Y receptor type 5(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166556(N*2*-[1-(4-Bromo-2-trifluoromethoxy-benzenesulfony...)
Affinity DataIC50: 8.90E+3nMAssay Description:Inhibitory activity against constitutively activated human Neuropeptide Y receptor Y5 transiently expressed in COS-1 cells using [125I]PYYMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166562(4-Bromo-N-[4-(quinazolin-2-ylaminomethyl)-cyclohex...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166564(N-{4-[(4-Dimethylamino-quinazolin-2-ylamino)-methy...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetMelanin-concentrating hormone receptor 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50166553(Propane-2-sulfonic acid {4-[(4-dimethylamino-quina...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibitory activity against mutated constitutively activated human Melanin concentrating hormone receptor 1 (CA-MCH-R1) stably expressed in HEK293 ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed